Search Results 291-300 of 15109 for TNF

1. A Study Investigating the Safety, Tolerability, Pharmacokinetics, and Effectiveness of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma - Mayo Clinic

   ... tumor necrosis factor agents) with the exception of pre-phase treatment with prednisone up to 100 mg daily for 7 days (or equivalent corticosteroid dose) ...

2. A Study Evaluating The Safety, Efficacy, And Pharmacokinetics Of Mosunetuzumab And A Combined Regimen Of Mosunetuzumab And Venetoclax In Participants With Relapsed Or Refractory Chronic Lymphocytic Leukemia - Mayo Clinic

   ... tumor necrosis factor agents) within 2 weeks prior to the first dose of study treatment; any other anti-cancer therapy, whether investigational or approved ...

3. Gastroenterology and Hepatology - Clinical trials

   The purpose of this study is to develop a biorepository of blood samples from cancer patients participating in the Gemini (IRB 19-006717) protocol.

4. News - Nilufer Taner, M.D., Ph.D. - Mayo Clinic

   Nilufer Taner, M.D., Ph.D. Neurologist. Request an Appointment · Overview · News ...

5. Publications - Gian Marco Conte, M.D., Ph.D. - Mayo Clinic

   ... tumor necrosis factor-alpha in primary CNS lymphoma. Blood. 2019 Jul 18; 134 (3):252-262 Epub 2019 May 22. View PubMed; Conte GM, Altabella L, Castellano A ...

6. A Study to Evaluate the Safety, Effectiveness and Microbiological Response of Orally Administered ABI-M201 in Subjects with Mildly-to-Moderately Active Ulcerative Colitis with Ongoing Mesalamine Treatment - Mayo Clinic

   ... TNF-alpha-antagonists, anti-integrin therapies, agents targeting IL-12 or IL-23, etc.). Known intolerance/allergic reaction to imipenem or metronidazole ...

7. Fatty liver disease (MASLD) - Doctors and departments - Mayo Clinic

   This liver condition is becoming more common in the Western world. Find out how to treat and prevent this potentially dangerous liver disease.

8. A Study to Evaluate Budesonide in Patients with Immune Mediated Enteropathies - Mayo Clinic

   Other immune mediating medications; for example, but not limited to, azathioprine, 6-mercaptopurine, cyclosporine, methotrexate, anti-TNF monoclonal ...

9. A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030) - Mayo Clinic

   ... TNF-α agents) within 2 weeks prior to initiation of study treatment or anticipation of need for systemic immunosuppressive medication during study treatment ...

10. A Study to Evaluate the Safety and Effectiveness of IFX-1 in Add-on to Standard of Care in Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) - Mayo Clinic

    Received CD20 inhibitor, anti-tumor necrosis factor treatment, abatacept, alemtuzumab, any other experimental or biological therapy, intravenous ...